Is DaVita stock undervalued?
As of July 2026, there is significant debate regarding the valuation of DaVita (DVA) stock. While some intrinsic valuation models and analyst price targets suggest the stock is trading well above its fair value—potentially overvalued by more than 22%—other metrics offer a different perspective. When looking at the price-to-earnings (P/E) ratio, DaVita trades at approximately 20.1x, which is lower than its own historical averages, its peers in the sector, and the broader U.S. healthcare industry. This discrepancy suggests that while the share price has built strong momentum and sits above traditional fair value anchors, it may still appear to be good value relative to its underlying fundamentals. Investors should carefully weigh this optimism against the company's risk factors before reaching a conclusion.
Related FAQs
Yes, "Dx" is a standard medical abbreviation used by healthcare professionals as shorthand for "diagnosis.
Warren Buffett does not hold shares of Diageo plc (trading under the ticker DEO) within Berkshire Hathaway's investment portfolio.
The Chief Executive Officer of Dollar Tree Inc. is compensated through a structured executive remuneration plan outlined in annual proxy filings. Total annual compensation for the chief executive officer typically ranges between 7.6 million and 9.
As of mid-2026, analyst consensus on DaVita (DVA) is mixed and suggests a cautious approach. Recent ratings indicate that 33% of analysts recommend a "Strong Buy," while 50% suggest "Holding" the stock, and 17% advise "Selling".
DaVita has undergone several rounds of layoffs and job cuts over the past few years, particularly between 2022 and 2024, as part of a multi-year restructuring and cost-cutting initiative.
DaVita (DVA) currently holds a consensus "Hold" rating among analysts. While 33% of analysts recommend a "Strong Buy," 50% suggest "Holding," and 17% advise "Selling.